Dr. James Inglese is an adjunct investigator in NHGRI's Genetics and Molecular Biology Branch.
… such as large synthetic compound libraries, existing pharmaceuticals , and naturally occurring plant or microbial … screening, large synthetic compound libraries, pharmaceuticals … james inglese, high-throughput screening, large synthetic compound libraries, pharmaceuticals … dr. james inglese is an adjunct …
Dr. Ajay Pillai is a program director in the Division of Genome Sciences at the National Human Genome Research Institute.
… institute as a staff scientist. prior to that at vertex pharmaceuticals working as a computational scientist. dr. …
Dr. Simona Volpi is a program director in the Division of Genomic Medicine at the National Human Genome Research Institute.
… the national institues of health (nih) and joined vanda pharmaceuticals as the associate director for …
Research at NHGRI
The Technology Transfer Office is responsible for transferring NHGRI technologies to the private sector and exchanging research materials with outside groups.
Careers and Training
Scientists and thousands of other professionals are using discoveries in genetics to revolutionize the world. This means careers in genetics and genomics are booming. And there are many other careers you don’t usually think of as science, like education, social work, and even law and the arts that are affected by this growth, creating even more career opportunities.
The Genetics/Genomics Competency Center now includes a new section on pharmacogenetics and pharmacogenomics.
Professional Development Programs
Provides exposure to the broader genomics community and experts in the field, with the opportunity to work on a genetics/genomics-related education projects under the mentorship of an ISCC-PEG member.
General Medicine IRB Panel #1 is responsible for protecting human subjects of research protocols conducted NHGRI, NHLBI and other NIH institute investigators.
Researchers are trying to understand a process whose rules are constantly being written and rewritten by cancer's rogue cells: who will more likely relapse.
Genomic analyses turned up genes that belong to inflammatory pathways.